Skip to main content
main-content

Lung and thoracic cancers

medwireNews coverage from the ESMO Congress in Munich 2018

21-10-2018 | Non-small cell lung cancer | ESMO 2018 | News

Candidate mutations underlying acquired resistance to osimertinib mapped

Analyses of the FLAURA and AURA3 trials presented at the ESMO 2018 Congress in Munich, Germany, shed light on the genetic mechanisms of acquired resistance to the third generation EGFR–tyrosine kinase inhibitor osimertinib.

31-10-2018 | Non-small cell lung cancer | ESMO 2018 | News

ALESIA confirms first-line alectinib benefit in Asian advanced NSCLC patients

The ALESIA trial comprising treatment-naïve patients with advanced anaplastic lymphoma kinase translocation-positive non-small-cell lung cancer confirms the systemic and intracranial efficacy of alectinib over crizotinib in an Asian population.

01-11-2018 | Non-small cell lung cancer | ESMO 2018 | News

Neoadjuvant erlotinib evaluated for EGFR-mutated stage IIIA-N2 NSCLC

The CTONG-1103 EMERGING trial investigators believe that neoadjuvant treatment with epidermal growth factor receptor–tyrosine kinase inhibitors for stage IIIA-N2 non-small-cell lung cancer warrants further investigation.

19-10-2018 | Non-small cell lung cancer | ESMO 2018 | News

Dual MET–EGFR inhibition promising for relapsed MET-high NSCLC

Combining the highly selective MET inhibitor tepotinib with gefitinib could benefit patients with non-small-cell lung cancer that has progressed on first-line treatment with an EGFR–tyrosine kinase inhibitor and has high levels of MET, suggest phase II trial results.

01-11-2018 | Immunotherapy | ESMO 2018 | News

Anti-PD-1 immunotherapy feasible for patients with HIV and cancer

A database analysis reported at the ESMO 2018 Congress in Munich, Germany, points to the feasibility of using immune checkpoint inhibitors in people living with HIV who develop cancer.

22-10-2018 | Non-small cell lung cancer | ESMO 2018 | Video

Mechanisms of acquired resistance to osimertinib in AURA3

Vassiliki Papadimitrakopoulou outlines the candidate molecular mechanisms of acquired osimertinib resistance as revealed in the AURA3 trial and discusses the possibilities for later lines of treatment (4:12).

Image Credits